| Clotting |
Factor IXa and Factor X |
Emicizumab |
Hemlibra |
L3 - No Data-Presumed Compatible |
| Clotting |
Terminal complement protein C5 |
Eculizumab |
Soliris |
L2 - Limited Data-Probably Compatible |
| Clotting |
Terminal complement protein C5 |
Ravulizumab |
Ultomiris |
L3 - No Data-Presumed Compatible |
| Clotting |
von Willebrand factor (VWF) |
Caplacizumab |
Cabliva |
L3 - No Data-Presumed Compatible |
| External |
B. anthracis toxins |
Obiltoxaximab |
Anthim |
L3 - No Data-Presumed Compatible |
| External |
B. anthracis toxins |
Raxibacumab |
|
L3 - No Data-Presumed Compatible |
| External |
C. diff. toxin B |
Bezlotoxumab |
Zinplava |
L3 - No Data-Presumed Compatible |
| External |
dabigatran |
Idarucizumab |
Praxbind |
L3 - No Data-Presumed Compatible |
| External |
SARS-CoV-2 |
Casirivimab |
Regen-COV |
L3 - No Data-Probably Compatible |
| External |
SARS-CoV-2 |
Cilgavimab |
Evusheld |
L3 - No Data-Presumed Compatible |
| External |
SARS-CoV-2 |
Imdevimab |
Regen-COV |
L3 - No Data-Probably Compatible |
| External |
SARS-CoV-2 |
Sotrovimab |
Xevudy |
L3 - No Data-Probably Compatible |
| External |
SARS-CoV-2 |
Tixagevimab |
Evusheld |
L3 - No Data-Presumed Compatible |
| Growth Factor |
FGF-23 |
Burosumab |
Crysvita |
L3 - No Data-Presumed Compatible |
| Growth Factor |
IGF-1R |
Teprotumumab |
Tepezza |
L3 - No Data-Presumed Compatible |
| Growth Factor |
VEGF-R-bind |
Bevacizumab |
Avastin, Mvasi, Zirabev |
L3 - No Data-Presumed Compatible |
| Growth Factor |
VEGF-R-bind |
Ranibizumab |
Lucentis |
L3 - No Data-Presumed Compatible |
| Hemophilia |
Tissue factor pathway |
Concizumab |
Alhemo |
L3 - No Data-Presumed Compatible |
| Hemophilia |
Tissue factor pathway |
Marstacimab |
|
L3 - No Data-Presumed Compatible |
| Immunicity |
B lymphocyte stimulator protein |
Belimumab |
Benlysta |
L3 - No Data-Presumed Compatible |
| Immunicity |
BCMA, CD-3 |
Elranatamab |
Elrexfio |
L3 - No Data-Presumed Compatible |
| Immunicity |
CCR4 |
Mogamulizumab |
Poteligeo |
L3 - No Data-Presumed Compatible |
| Immunicity |
CD-20 |
Ocrelizumab |
Ocrevus |
L3 - Limited Data-Presumed Compatible |
| Immunicity |
CD-20 |
Rituximab |
Rituxan |
L3 - Limited Data-Presumed Compatible |
| Immunicity |
CD-20 |
Ublituximab |
Briumvi |
L3 - No Data-Presumed Compatible |
| Immunicity |
CD20, CD3 |
Odronextamab |
|
L3 - No Data-Presumed Compatible |
| Immunicity |
FcRN receptor |
Rozanolixizumab |
Rystiggo |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-1 beta |
Canakinumab |
Citomix, Ilaris |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-13 |
Lebrikizumab |
Ebglys |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-17A |
Ixekizumab |
Taltz |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-17A |
Secukinumab |
Cosentyx |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-17A, IL-17F |
Bimekizumab |
Bimzelx |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-17RA |
Brodalumab |
Siliq |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-1R |
Anifrolumab |
Saphnelo |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-2 (CD25) |
Daclizumab |
Zinbryta |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-2 (CD25) |
Basiliximab |
Simulect |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-23 |
Guselkumab |
Tremfya |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-23 |
Mirikizumab |
Omvoh |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-23 |
Risankizumab |
Skyrizi |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-23 |
Tildrakizumab |
Ilumya |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-23 |
Ustekinumab |
Stelara |
L3 - Limited Data-Presumed Compatible |
| Immunicity |
IL-36 |
Spesolimab |
Spevigo |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-4 |
Dupilumab |
Dupixent |
L3 - Limited Data-Presumed Compatible |
| Immunicity |
IL-5 |
Benralizumab |
Fasenra |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-5 |
Reslizumab |
Cinqair |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-5 (eosinophil) |
Mepolizumab |
Nucala |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-6Ra-bind |
Sarilumab |
Kevzara |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-6Ra-bind |
Satralizumab |
Enspryng |
L3 - No Data-Presumed Compatible |
| Immunicity |
IL-6Ra-bind |
Tocilizumab |
Actemra |
L3 - Limited Data-Presumed Compatible |
| Immunicity |
INFg |
Emapalumab |
Gamifant |
L3 - No Data-Presumed Compatible |
| Immunicity |
Integrin, a4 |
Natalizumab |
Tysabri |
L3 - Limited Data-Presumed Compatible |
| Immunicity |
Integrin, a4b7 |
Vedolizumab |
Entyvio |
L3 - Limited Data-Presumed Compatible |
| Immunicity |
TNF |
Etanercept |
Enbrel |
L2 - Limited Data-Probably Compatible |
| Immunicity |
TNFa |
Adalimumab |
Humira, Imraldi |
L3 - Limited Data-Presumed Compatible |
| Immunicity |
TNFa |
Certolizumab Pegol |
Cimzia |
L2 - Limited Data-Probably Compatible |
| Immunicity |
TNFa |
Golimumab |
Simponi |
L3 - Limited Data-Presumed Compatible |
| Immunicity |
TNFa |
Infliximab |
Avsola, Inflectra, Remi- cade, Renflexis |
L3 - Limited Data-Presumed Compatible |
| Lipids |
PCSK9 |
Alirocumab |
Praluent |
L3 - No Data-Presumed Compatible |
| Lipids |
PCSK9 |
Evolocumab |
Repatha |
L3 - No Data-Presumed Compatible |
| Migraine |
CGRP |
Eptinezumab |
Vyepti |
L3 - No Data-Presumed Compatible |
| Migraine |
CGRP |
Erenumab |
Aimovig |
L3 - No Data-Presumed Compatible |
| Migraine |
CGRP |
Fremanezumab |
Ajovy |
L3 - No Data-Presumed Compatible |
| Migraine |
CGRP |
Galcanezumab |
Emgality |
L3 - No Data-Presumed Compatible |
| Other |
CD3 |
Teplizumab |
Tzield |
L3 - No Data-Presumed Compatible |
| Other |
IgE |
Omalizumab |
Xolair |
L2 - Limited Data-Probably Compatible |
| Other |
kallikrein |
Lanadelumab |
Takhzyro |
L3 - No Data-Presumed Compatible |
| Other |
P-selectin |
Crizanlizumab |
Adakveo |
L3 - No Data-Presumed Compatible |
| Other |
RANKL |
Denosumab |
Prolia, Xgeva |
L3 - No Data-Presumed Compatible |
| Other |
sclerostin |
Romosozumab |
Evenity |
L3 - No Data-Presumed Compatible |
